TriSalus Life Sciences Inc. Common Stock (TLSI)

About TLSI

TriSalus Life Sciences, Inc. engages in the research, development, and commercialization of drug delivery technology platform and immuno-oncology therapeutics to improve outcomes for patients with difficult-to-treat liver and pancreatic cancers in the United States. It offers Pressure-Enabled Drug Delivery (PEDD) infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization an…

Sector

Health Care

Industry

Medical Specialities

Employees

102

Website

trisaluslifesci.com/

Fundamentals

1-day range

$4.7$5.24

Market cap

$291.73M

P/E (trailing)

—

P/E (forward)

-19.32

EPS (trailing)

$-0.68

Dividend yield

—

Beta

0.43

Avg. volume

307.5K

Forecasts

4 analyst ratings

TriSalus Life Sciences Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• TLSI

  TriSalus Life Sciences Inc. Common Stock

  $4.85

  ▼ 1.62%
  Market cap $291.73MP/E —
  $2.2$7.95
• ACH

  Accendra Health Inc. Common Stock

  $1.22

  ▲ 0.83%
  Market cap $261.15MP/E —
  $0.9337$5.69
• YDES

  YD Bio Limited Ordinary Shares

  $4.8

  ▲ 24.03%
  Market cap $162.91MP/E —
  $1.7$25
• KEQU

  Kewaunee Scientific Corporation Common Stock

  $37.78

  ▼ 0.50%
  Market cap $107.27MP/E 10.89
  $33.27$59
• BNR

  Burning Rock Biotech Limited American Depositary Shares

  $10.19

  ▲ 1.90%
  Market cap $93.65MP/E —
  $6.79$41.72
• SERA

  Sera Prognostics Inc. Class A Common Stock

  $2.07

  ▲ 0.49%
  Market cap $78.32MP/E —
  $1.56$3.95
• AMS

  American Shared Hospital Services Common Stock

  $1.47

  ▲ 0.68%
  Market cap $9.84MP/E —
  $1.25$3.11

P/E shows — for peers not currently carrying a live signal of their own.

Institutional Ownership

March 31, 2026

Total shares held

20.41M

Total value held

$79.16M

Institutional holders

81